Irving-based Caris Life Sciences has raised $1.86 billion in capital since 2018 — most recently securing $168 million dollars.
“This financing includes participation by some of the most knowledgeable healthcare investors with deep domain expertise and appreciation of the Caris platform and opportunity,” Brian J. Brille, vice chairman and EVP of Caris, said in a statement.
Founder and CEO David Halbert said that the recent raise will be used bring the startup’s science and technology to ‘as many patients as possible.’
The recent raise was led by Stamford, CT-based Braidwell LP, a life science-focused investment firm. It is also an existing investor.
“We’re pleased to continue our relationship with Caris, and we believe Caris is well-positioned as a precision medicine leader in this dynamic sector,” said Braidwell Partner, Narendra Nyak.
For the full story, go to Dallas Innovates.
